

Volume 2

A survey of the biotransformations of drugs and chemicals in animals

Edited by D. R. Hawkins

Biotransformations

A survey of the biotransformations of drugs and chemicals in animals

Volume 1

Edited by

D. R. Hawkins

Huntingdon Research Centre Ltd







British Library Cataloguing in Publication Data

Biotransformations: a survey of the biotransformations of drugs and chemicals in animals. Vol. 1 1. Animals. Effects of drugs I. Hawkins, D. R. 591.19 ISBN 0-85186-157-1

© The Royal Society of Chemistry 1988

All Rights Reserved

No part of this book may be reproduced or transmitted in any form
or by any means — graphic, electronic including photocopying, recording,
taping or information storage and retrieval systems — without written
permission from The Royal Society of Chemistry

Published by The Royal Society of Chemistry, Burlington House, London W1V 0BN

Set by Unicus Graphics Ltd, Horsham, West Sussex and printed in Great Britain by Whitstable Litho Ltd, Whitstable, Kent

Preface

Investigation of biotransformation processes has been a rapidly expanding aspect of xenobiotic metabolism. This has been brought about by the increasing realization of the important influence of biotransformation on pharmacological activity and toxicity and the parallel rapid advances in technology in analytical chemistry and in particular physico-chemical techniques such as mass spectrometry.

In drug discovery and development extrapolation of activity from *in vitro* pharmacological screens to animals *in vivo* and finally to man can be improved by consideration of the impact of biotransformation on the compound in different systems. Consideration of the structures of compounds shown to be active in *in vitro* screens would indicate compounds likely to be inactive *in vivo* due to rapid biotransformation. Structural modifications can then be introduced to inhibit metabolism at key positions in the molecule.

Species differences in toxicity are commonplace and are often attributable to differences in biotransformation pathways. An understanding of the mechanisms of toxicity may help to extrapolate the relevance of findings in laboratory animals to human exposure.

Prediction of biotransformation pathways would be an ideal goal but one which we are far from achieving. However, a key to knowing how close we can get to this goal is to ensure that full use can be made of available knowledge. This series has been devised to bring together all current information on biotransformations in a readily accessible form. It is hoped that this will provide a valuable database which will increase awareness of patterns in species differences and influences of chemical structure on biotransformation with a view to increasing the ability to make predictions for new compounds.

The series will cover biotransformations of chemical entities whether they are pharmaceuticals, agrochemicals, food additives, or environmental or industrial chemicals in vertebrates of the animal kingdom, which includes mammals, birds, fish, amphibians, and reptiles. This first volume broadly covers the literature for the calendar year 1987 although it has not been possible to include material in late issues of some journals. This will be included in the second volume which will cover 1988 literature. We have attempted to include all relevant literature but realize that this goal may not have been achieved. The Editor would be grateful to receive copies of omitted papers which could be included in a subsequent volume.

Arrangement of Material and Access

An overview chapter has been prepared which contains highlights such as novel biotransformation, mechanisms of toxicity, and notable species differences. The abstracts are arranged according to compound class, although there may be cases where allocation to one or another class is somewhat subjective. It has been considered valuable to be able to access information on the biotransformation of compounds with similar structural features. For

this purpose the concept of key functional groups has been developed. Selection and naming of these groups has evolved during preparation of the material. For each compound functional groups have been selected where biotransformation has been shown to occur but in addition groups have also been included where biotransformation has not taken place. A list of the functional groups is provided which may be referred to before proceeding to the corresponding index. Two other indexes have been included containing compound names and types of biotransformation processes respectively.

In the precis for each compound certain key information has been included when available. Where radiolabelled compounds have been used the position(s) of labelling have been indicated on the structure. Comments on the source of metabolites and information on the quantitative importance of individual metabolites such as percentage material in the sample or percentage administered dose are given where possible. Also, in order to provide a perspective on the criteria for identification, the procedures used for separation and isolation of metabolites and structural assignments such as chromatographic and physico-chemical techniques and use of reference compounds have been discussed.

The Editor

Contributors

- P. Batten ICI Central Toxicology Laboratory, Alderley Park, Macclesfield, Cheshire, SK10 4TJ, UK
- A. Bell Glaxo Group Research, Ware, Herts., SG12 0DJ, UK
- P. Farmer MRC Toxicology Unit, Medical Research Council Laboratories, Woodmansterne Road, Carshalton, Surrey, SM5 4EF, UK
- **D. R. Hawkins** Huntingdon Research Centre, Huntingdon, Cambs., PE18 6ES, UK
- **D. Kirkpatrick** Huntingdon Research Centre, Huntingdon, Cambs., PE18 6ES, UK
- M. Prout ICI Central Toxicology Laboratory, Alderley Park, Macclesfield, Cheshire, SK10 4TJ, UK

Key Functional Groups

R may be any unspecified group including H. Where two or more R groups are indicated these may be the same or different groups. Where aromatic rings or other cyclic systems are shown they may also contain substituents when they are not specified as part of the key functional group.

Acetal	T _o X _H	Alkoxyphenyl	RCH ₂ O
Acetamide	O CH ₃ CNHR	Alkyl alcohol	RCH ₂ OH
Acetamide	Mana House	sec-Alkyl alcohol	R СН—ОН
N-Acetyl aryl amine	CH3CNH—	Alkyl aldehyde	RCH ₂ CHO
Acetylthio	CH ₃ CSR	Alkyl amide	O RCNHCH ₂ R
Alanine	CH ₃ H ₂ NCHCO ₂ H	Alkyl amine	RCH ₂ NH ₂
tert-Alcohol	R R C OH Proside WALA	Alkyl tert-amine	$R \rightarrow N-R$
Alkadiene	_c=cH-cH=c	sec-Alkyl amine	R CH—NHR
Alkane	CH ₃ (CH ₂) _n R	tert-Alkyl amine	R R C—NHR
iso-Alkane	RCH ₂ CH—	Alkylamino	RCH ₂ NH—
Alkene	c=c contains while	iso-Alkylamino	R CHNH-

Alkyl aryl amide	RC—N—CH ₂ R	N-Alkyl cycloalkylamine	(CH ₂) _n NHCH ₂ R
	R—N—CH.R	Alkylcyclohexane	RCH ₂ —
Alkyl aryl amine	R—N—CH ₂ R	Alkyl ester	O RCOCH ₂ R
iso-Alkyl aryl amine	R—N—CH—R	iso-Alkyl ester	O RCOCH R
		Alkyl ether	RCH ₂ OR
sec-Alkyl aryl amine	R-N-CH ₂ CH-R	Alkyl hydrazine	RCH ₂ NHNHR
Alkyl aryl ether	RCH ₂ O —	N-Alkyl imide	R—N—CH ₂ R
Alkyl aryl sulphoxide	RCH ₂ S	Alkyl ketone	RCH ₂ CR
Alkyl aryl thioether	RCH ₂ S	Alkylphenyl	RCH ₂
Alkyl carboxamide	O RCH ₂ CNHR	iso-Alkylphenyl	R C H
Alkyl carboxylic acid	о RCH ₂ COH	N-Alkylpiperazine	RN NCH ₂ R
—nu n:	Alkylamino	Alkyl quaternary ammonium	
iso-Alkyl carboxylic acid	CHCOH	Alkyl sulphate	RCH ₂ OSO ₃ H

Alkyl sulphonate	RCH ₂ OSO ₂ R		ů
Alkyl sulphoxide	O RCH ₂ SR	Anthraquinone	
Alkyl thioether	RCH ₂ SR	Aryl acetic acid	С н₂со₂ н
Allyl amine	RCH=CH-NH ₂	Aryl aldehyde	СНО
Allylic alcohol	R RCH=CHCHOH	Arylalkene	CH=CHR
Amidine	N(R) ₂ R—C == NR	Arylalkyl	CH ₂ R
Amidoxime	NOH RCNH ₂	Aryl tert-alkyl	$C \subset \mathbb{R}^{R}$
Amino acid	RCHNH ₂ CO ₂ H	Aryl amide	0 NHCR
Aminoimidazole	H ₂ N $\stackrel{N}{\longleftarrow}$ N $\stackrel{N}{\longleftarrow}$ H	Aryl amine	NHR
Aminopyridine	NH ₂	Aryl amino acid	CH—NH ₂
Aminothiophene	NH ₂	Aryl carboxamide	O CNHR
Androsten-3-one		Aryl carboxylate	OCOR

Aryl carboxylic acid	Сон	Aryl thioether	SR SR
Aryl ester	OCR	Azobenzene	N=NR
Aryl ether	OR OR	Barbiturate	R NR
Arylethylene			
Aryl hydrazine	NHNH ₂	Benzanthracene	and and an analysis of the second
Arylhydroxymethyl	сн ₂ он	Benzhydrol	OH C R
N-Arylimine	N=R	Benzhydryl	<u>С</u> Н——
Aryl ketone	CR CR	Benzidine	R NH NH
Arylmethyl	CH ₃		
N-Arylnitrosamine	NNO NNO	Benzimidazole	H N N N N N N N N N N N N N N N N N N N
Arylnitroso	R NO	Benzofuran	
Aryl propionic acid	CH ₃ CHCO ₂ H	Benzo[a]pyrene	

Benzo $[c]$ phenanthrene		Bromophenyl	Br—
	R	iso-Butyl	СН ₃ СНСН ₂ —
Benzodiazepine		tert-Butyl	CH ₃ C—
Benzyl	CH_2R		CH ₃
Benzyl alcohol	СН₂ОН	Chiral carbon	R^1 — C^* — R^3
Benzyl amine	\sim	Chloroacetamide	O CICH ₂ CNHR
Benzyl bromide	CH ₂ Br		O CICH ₂ CR
Benzyl ether	CH ₂ OR	Chloroacetyl	CICH ₂ CR
Benzyl nitrile	CH ₂ CN	Chloroalkene	CICH=CHR
		Chloroalkyl	CICH R
Biphenyl	Today tollaich	Chlorobenzoyl	CI C
Bromoacetyl	O BrCH ₂ CR	Chlorobiphenyl	
Bromoalkane	BrCH ₂ R	-5	(C1) ₀
Bromoalkyl	BrCH R	N-Chloroethyl	cich ₂ ch ₂ N

xiii

N-Cyclopropylmethyl R-NCH2

Cholanic acid

Cholestenone

Chrysene

Coumarin

Cycloalkane/cycloalkyl

Cyclohexane/cyclohexyl

Cyclohexanone

Cyclopentenone

Cyclopropyl carboxylate

Cytidine

Cytosine

Dialkyl amine

Dialkylamino

Dialkylaminoalkyl

Dialkyl aryl amine

Dialkyl ether

Dialkylisoxazole

Dialkyl thioether

Diaryl thioether

 NH_2

RCH2OCH2R

RCH₂SCH₂R

Dibenzofuran		Ethynyl	R—C≡C—R
		Fatty acid (saturated)	R(CH ₂),CO ₂ H
Dichloroalkene	CI CI CI	Fatty acid (unsaturated)	R(CH=CH),CH2CO2H
Digitoxigenin	- Description of the combat	Fluorene	
Dihydropyran		Fluoroacetyl	0
Dihydropyridine			R
		Fluoroalkyl	FCH ₂ CH R
Dihydroquinoline			NH ₂
Dimethylamide	RCN CH ₃	Fluorocytosine	N F F P P P P P P P P P P P P P P P P P
Dimethylaminoalkyl	H ₃ C NCH ₂ R	Fluorouracil	HN F
	H ₃ C CH ₃		O NH
Dimethylcyclopropyl	- A	Formamide RI	инсно
Disulphide	R—S—S—R	Furan	
Dithiocarbamate	CH ₂ NHCS ⁻ CH ₂ NHCS ⁻ CH ₂ NHCS ⁻ S	Furfural	СНО
	Merbanesuiphonnie CH SC	Glutathione	о—мнснсо—мнсн ₂ соон
Dithiolane		NH ₂	CH ₂ SH
Epoxide		Glycolamide	OH SHIFOSEDMAL

Glycoside	CH ₂ OH HO√OR	Iminecarboxylate	O MANAGEMENT OF THE PROPERTY O
	но он	Indane	Sichlercoullers (
Guanidine	R—NHCNH ₂	Indene	
Hexose	HO ~ OH	Indole	H X H
Undontain	° NH	Iodoalkyl	ICH ₂ R
Hydantoin	N O	Isoprenoid	
Hydrazide	O RCNHNH ₂	Isoquinoline	₩ N
Hydrazine	RNHNH ₂	Lactam	(CH ₂) _n
Hydroperoxide	R R СНООН		Smethylcycloproco
N-Hydroxy	R N—OH	Lactone	(CH ₂) ₀
N-Hydroxy sulphate	$R > N - OSO_3H$	Leucine	H ₃ C CHCH ₂ CHCOOH
Imidazole	W N N N N N N N N N N N N N N N N N N N	Methanesulphonate	CH ₃ SO ₂ OR
Imidazoline		o-Methoxyphenol	OCH ₃

Methoxyphenyl	OCH ₃	N-Methylnitrosamine
N-Methyl alkyl amine	R N-CH ₃	Methylphenyl H ₃ C —
Methyl amide	O RCNHCH ₃	Methylphosphinoyl CH ₃ P—OR
N-Methylamidine	NH R—CNHCH ₃	O-Methylphosphorodithioate CH_3O CH_3O CH_3O CH_3O
Methylamino	CH ₃ NHR	O-Methylphosphorothioate CH_3O CH
N-Methyl aryl amine	NHCH3	CH ₃ 0 (0)
Methyl carbamate	O RNHCOCH ₃	N-Methylpiperidine N-CH ₃
Methyl carboxylate	CH ₃ COR	N-Methylpurine $\stackrel{RN}{\underset{N}{\bigvee}}$ $\stackrel{R}{\underset{N}{\bigvee}}$ $\stackrel{R=H}{\underset{N}{\bigvee}}$ or CH_3
Methylcyclohexene Methyl ether	CH ₃ OR	Methylpyrimidine NHR CH ₃
N-Methylimidazole	CH ₃	N -Methylpyrrolidine $\begin{pmatrix} N \\ CH_3 \end{pmatrix}$
Methylindole	CH3 N	N-Methylpyrrolidone CH ₃

xvii

Methylquinoxaline	H ₃ C N	Nitrofuran	NO ₂
Methyl sulphonate	CH ₃ OSO ₂ R	Nitroimidazole	N NO ₂
Methylsulphinyl	CH ₃ SR	Nitrophenyl	NO ₂
N-Methyltetrahydropyridir	$ \begin{array}{cccc} & & & \\ & $	Nitrosamine	R NNO
	iborody sighthal	Nucleoside	- Alikatethylaeridhe
Methyl thioether	CH ₃ SR	Octyl	сн ₃ (сн ₂) ₇ -
Monoclonal antibody	P Nethylphosphorn		
Morphinan	NR	Oestradiol	HO CH ₃ OH
Morpholine		Oestren-3-one	OH OH
Naphthalene	9	Oestrone	
Naphthaquinone		Organoarsenic	(R) ₃ As
Nitrile	RCN	Oxazole	o N michael edus M

xviii

Oxazolidinone	√o NR o NR	Phthalazine
Oxime	RCН──NOН	R
Oximino	R=N-OR	Phthalidyl
Pentyl	CH ₃ (CH ₂) ₄ -	Ö
Peptide	O O	Piperazine R—N N—R
	Ř Ř oн	Piperidine
Phenol	Suffamily .	Piperidinedione
Phenoxybenzyl	0-CH ₂ R	Polycyclic aromatic —
		Polycyclic aromatic amine
N-Phenyl	$R \sim N \sim 10^{-10}$	сн₂он
Phenylethyl	CH ₂ CH ₂ R	Prednisolone
Phosphoramide	RO P-NHR	
Phosphoramidothic	pate RO P OR	Pregnadiene
	Axogogicans-y	
Phosphorothioate	RO P—SR	Pregnene